BARCELONA — Byetta, a glucagon-like peptide-1 agonist approved for the treatment of type 2 diabetes mellitus, improved hepatic insulin resistance and adipose tissue in men with nonalcoholic fatty liver disease, according to a poster presentation ... Healio, 1 month ago
A US advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination created to be both effective and convenient. Although the FDA is not bound ...Equilibrio Informativo, 18 hours ago U.S. panel backs approval of Sanofi combination diabetes drug Yahoo! Singapore, 3 days ago US panel backs approval of Sanofi combination diabetes drug The Malaysian Times, 3 days ago UPDATE 2-U.S. panel backs approval of Sanofi combination diabetes drug Reuters UK, 3 days ago
What Drives Sanofi's Valuation? ( Continued from Prior Part ) Diabetes and Cardiovascular franchise revenue Sanofi (SNY) has reorganized its Diabetes and Cardiovascular franchise, making it one of the largest revenue contributors for Sanofi's ...Yahoo! Finance UK and Ireland, 4 days ago
By Toni Clarke (Reuters) - A preliminary review by the U.S. Food and Drug Administration questioned the usefulness of a combination diabetes drug made by Sanofi SA's and said it was unclear whether one component, lixisenatide, contributed to its ...Yahoo! Singapore, 5 days ago UPDATE 1-FDA staff question utility of Sanofi diabetes drugs London South East, 5 days ago FDA staff question utility of Sanofi diabetes drugs Pharma Live, 5 days ago UPDATE 2-FDA staff question usefulness of Sanofi diabetes drugs Reuters UK, 5 days ago
Global Diabetes Injection Pens Market Report Provides a Comprehensive View & Included a Detailed of Competitive Scenario and Product Portfolio of Key Vendors.
The report provides a comprehensive view on the diabetes injection pens; we have included a detailed competitive scenario and product portfolio of key vendors. The report segments the diabetes injection pens market on the basis of type of devices, ...Digital Journal, 5 days ago Global Antidiabetics Market, Size and Forecasts in Terms of Revenue (USD Million) for the Period 2016 to 2020. Digital Journal, 1 week ago Non-alcoholic Steatohepatitis Therapeutics Market 2016 to 2020 Before It's News, 2 weeks ago Diabetes Injection Pens Market 2016-2020 Industry Examined by Syndicate Market Research Digital Journal, 3 weeks ago
More from: , Digital Journal...and 2 other sources
Intarcia recently released reassuring results from a heart safety study of ITCA 650 a small GLP-1 mini-pump device to treat type 2 diabetes showing it meets the FDA's heart safety pre-approval requirements. The device continuously releases ...diaTribe, 5 days ago Promising revolution, Intarcia's diabetes device poised for filing pharmaphorum, 2 weeks ago
Comments NEW YORK, March 3, 2016 /PRNewswire/ -- INTRODUCTION Peptide therapeutics, due to their numerous advantages such as high selectivity, stability, efficacy, safety, bioavailability and tolerability offer a number of benefits over other ...AndhraNews.net, 6 days ago
By Grant Zeng, CFA NASDAQ:ORMP On May 18, 2016, Oramed Pharmaceuticals Inc. (ORMP) announced positive top-line data from its Phase IIb study of ORMD-0801 in patients with type 2 diabetes. The study achieved its primary objective: a significant ...Yahoo! Finance, 1 week ago
A round-up of this week's top digital healthcare news. Marco Ricci reports. Marco Ricci Release the drones The concept of drone delivery felt like a pipedream when a certain online shopping giant demonstrated its prototype last year. ...pharmaphorum, 2 weeks ago
Antares Pharma Inc. (NASDAQ: ATRS ) Q1 2016 Earnings Conference Call May 9, 2016 08:30 ET Executives Jack Howarth - Vice President, Corporate Affairs Bob Apple - President and Chief Executive Officer Jim Fickenscher - Senior Vice ...Seeking Alpha, 2 weeks ago Insider Buying At Antares Pharma Seeking Alpha, 2 months ago
on your WebpageAdd Widget >Get your members hooked!